Sage Therapeutics, recently acquired by Supernus Pharmaceuticals, will lay off its entire staff of employees.
Per a June 26 WARN notice, the layoffs will take effect on August 22 and will include the company’s 338 full-time employees.
In Sage’s first quarter regulatory filing, the company noted that as of April 22, 2025, it employed 338 full-time employees, including 98 in R&D and 240 in sales, general and administrative areas. This was what was left following a reorg intended to support the ongoing launch of Zurzuvae, revealed in October 2024. That reorg had come with leadership changes, as well as a 33% workforce reduction, which included 55% of the company’s R&D team.
The recent mass layoff comes less than two weeks after it was announced that Supernus Pharmaceuticals would acquire Sage through a tender offer for $8.50 per share in cash — a deal worth approximately $561 million. Key to the deal for Supernus is Sage's marketed drug, Zurzuvae capsules, which became the first FDA approved oral drug designed to treat postpartum depression in adults in August 2023. Zurzuvae was jointly develop and commercialized with Biogen and as such, Supernus will report collaboration revenue that is 50% of total net revenue Biogen records for Zurzuvae in the U.S.